Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20034082 | 0.87 | HPGD (0.46) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL18148233 | 0.86 | ALDH1A1 (0.47) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL1707182 | 0.86 | HPGD (0.46) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL14546468 | 0.85 | ALDH1A1 (0.44) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL12221860 | 0.84 | HPGD (0.48) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL10031015 | 0.83 | HPGD (0.51) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL18510178 | 0.83 | HPGD (0.51) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL21954020 | 0.82 | ALDH1A1 (0.48) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL14655047 | 0.81 | HPGD (0.47) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL14857367 | 0.81 | HPGD (0.53) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981752-B2 | Tumor associated monocyte/macrophage binding peptide and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240150397-A1 | TARGETED DELIVERY SYSTEM AND METHODS OF USE THEREFOR | Sanford Burnham Prebys Medical Discovery Institute | 2024-05-09 | — | — | US | disclosed |
| US-20230173097-A1 | METHODS AND COMPOSITIONS RELATED TO PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2023-06-08 | — | — | US | disclosed |
| EP-2250278-B1 | METHODS AND COMPOSITIONS RELATED TO PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | BURNHAM INSTITUTE FOR MEDICAL RES (US) | 2023-04-05 | — | — | EP | disclosed |
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220175941-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2022-06-09 | — | — | US | disclosed |
| US-20220119450-A1 | BI-SPECIFIC EXTRACELLULAR MATRIX BINDING PEPTIDES AND METHODS OF USE THEREOF | UNIVERSITY OF TARTU (EE) | 2022-04-21 | — | — | US | disclosed |
| US-11260133-B2 | Methods and compositions related to peptides and proteins with C-terminal elements | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2022-03-01 | — | — | US | disclosed |
| EP-3921329-A1 | BI-SPECIFIC EXTRACELLULAR MATRIX BINDING PEPTIDES AND METHODS OF USE THEREOF | University of Tartu (EE) | 2021-12-15 | — | — | EP | disclosed |
| US-11077212-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20100120679-A1 | Targeting NBS1-ATM Interaction To Sensitize Cancer Cells To Radiotherapy And Chemotherapy | SOUTHERN RESEARCH INSTITUTE (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090233993-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GSK3 ACTIVITY AND USES THEREOF | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090226372-A1 | METHODS AND COMPOSITIONS RELATED TO PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-06-18 | — | — | US | disclosed |
| US-20090029924-A1 | Targeting Host Proteinases as a Therapeutic Strategy Against Viral and Bacterial Pathogens | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-01-29 | — | — | US | disclosed |
| US-7332277-B2 | Methods for detection of genetic disorders | RAVGEN, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20080008650-A1 | ENDOMETRIOSIS CELL TARGETING PEPTIDE AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2008-01-10 | — | — | US | disclosed |
| US-20070292387-A1 | TRANSMUCOSAL DELIVERY OF PHARMACEUTICAL ACTIVE SUBSTANCES | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-12-20 | — | — | US | disclosed |
| US-20070219134-A1 | LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS | THE BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2007-09-20 | — | — | US | disclosed |
| US-20070122835-A1 | Methods for detection of genetic disorders | RAVGEN, INC. | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120679-A1 | Targeting NBS1-ATM Interaction To Sensitize Cancer Cells To Radiotherapy And Chemotherapy | ATM, MRE11, DCLRE1A | HPGD 4383/4885SMN1; SMN2 2092/4885RAB9A 2451/4885 |
| US-20090226372-A1 | METHODS AND COMPOSITIONS RELATED TO PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | CD2BP2, CLTC, CLTA | HPGD 4595/4885SMN1; SMN2 2986/4885RAB9A 1903/4885 |
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | MKI67, ANXA4, ANXA3 | HPGD 3416/4885SMN1; SMN2 3989/4885RAB9A 707/4885 |
| US-11260133-B2 | Methods and compositions related to peptides and proteins with C-terminal elements | CD2BP2, CLTC, CLTA | HPGD 4595/4885SMN1; SMN2 2986/4885RAB9A 1903/4885 |
| US-20070292387-A1 | TRANSMUCOSAL DELIVERY OF PHARMACEUTICAL ACTIVE SUBSTANCES | SI, PIGS, MUC1 | HPGD 1112/4885SMN1; SMN2 3338/4885RAB9A 2419/4885 |
| US-20080008650-A1 | ENDOMETRIOSIS CELL TARGETING PEPTIDE AND USES THEREOF | ESR2, PROKR1, CXCL12 | HPGD 3058/4885SMN1; SMN2 4512/4885RAB9A 2039/4885 |
| US-20090233993-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GSK3 ACTIVITY AND USES THEREOF | GSK3B, GSK3A, GSKIP | HPGD 3050/4885SMN1; SMN2 2136/4885RAB9A 3135/4885 |
| US-20090156560-A1 | TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE INHIBITORS AND USES THEREOF FOR TREATING VASCULAR CALCIFICATION | ALPL, CNDP2, ALPI | HPGD 1367/4885SMN1; SMN2 4792/4885RAB9A 3655/4885 |
| US-20070219134-A1 | LYMPHATIC ZIP CODES IN TUMORS AND PRE-MALIGNANT LESIONS | SLC39A3, SLC39A11, CCL2 | HPGD 3422/4885SMN1; SMN2 4415/4885RAB9A 899/4885 |
| US-20090029924-A1 | Targeting Host Proteinases as a Therapeutic Strategy Against Viral and Bacterial Pathogens | SERPINB1, TMPRSS15, HPN | HPGD 2777/4885SMN1; SMN2 3740/4885RAB9A 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.